MRI and PET in Mouse Models of Myocardial Infarction
December 19th, 2013
12K views
We describe how to perform MRI and PET imaging of the mouse heart. The protocol is tailored to assess treatment efficacy in models of myocardial infarction and heart failure.
Overview
This article describes a protocol for assessing treatment efficacy in mouse models of myocardial infarction and heart failure using MRI and PET imaging. The procedure involves sequential imaging to evaluate heart response to treatments.
Key Study Components
Area of Science
- Neuroscience
- Cardiology
- Imaging Techniques
Background
- Myocardial infarction and heart failure are significant health issues.
- Imaging techniques like MRI and PET provide insights into cardiac function.
- Assessing treatment efficacy is crucial for developing new therapies.
- This protocol allows for in vivo evaluation of heart response.
Purpose of Study
- To assess the efficacy of new treatment strategies for myocardial infarction.
- To utilize MRI and PET imaging for comprehensive evaluation.
- To provide a protocol that can be replicated in research settings.
Methods Used
- Performing MRI examination on the mouse heart.
- Transferring the animal to a PET scanner for imaging.
- Conducting PET imaging to assess heart function.
- Performing offline data analysis of MRI and PET scans.
Main Results
- Results demonstrate the heart's response to treatment at multiple levels.
- Data from MRI and PET imaging provide complementary insights.
- The protocol allows for effective evaluation of treatment efficacy.
- Findings can guide future research in cardiac therapies.
Conclusions
- The combined use of MRI and PET imaging is effective for assessing cardiac treatments.
- This protocol can enhance understanding of myocardial infarction therapies.
- Future studies can build on this methodology for improved cardiac care.
Frequently Asked Questions
What is the significance of using MRI and PET imaging?
MRI and PET imaging provide detailed insights into heart function and treatment efficacy.
How does this protocol improve treatment assessment?
It allows for in vivo evaluation of heart response to therapies, enhancing research accuracy.
Can this protocol be applied to other models?
While tailored for myocardial infarction, it may be adapted for other cardiac conditions.
What are the main outcomes of this study?
The study shows the heart's response to treatment through comprehensive imaging data.
Is offline data analysis necessary?
Yes, offline analysis is crucial for interpreting the imaging results accurately.
What future research could this protocol support?
It can support research aimed at developing new therapies for heart diseases.
Executive Industry Relevance
Integrating MRI and PET imaging in mouse models of myocardial infarction enables high-resolution, quantitative assessment of cardiac structure, function, and metabolic activity in vivo. This dual-modality approach supports predictive confidence in evaluating candidate therapies and informs early-stage portfolio decisions by providing translationally relevant endpoints. The workflow enhances mechanistic de-risking and accelerates the transition from discovery to preclinical validation in cardiovascular drug development.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables rigorous interrogation of therapeutic hypotheses in disease-relevant cardiac models.
- Supports functional target validation by quantifying infarct size and metabolic recovery.
- Facilitates mechanistic de-risking through multimodal imaging outputs.
- Provides translational endpoints for portfolio triage and prioritization.
Screening & Assay Development
- Establishes validated imaging protocols for reproducible assessment of cardiac function and viability.
- Delivers quantitative metrics such as ejection fraction, infarct size, and FDG uptake for compound evaluation.
- Enables high-throughput, standardized workflows for screening cardioprotective agents.
- Supports assay scalability and cross-study comparability through robust segmentation and co-registration.
Translational & Preclinical Research
- Aligns imaging biomarkers with clinical endpoints for translational continuity.
- Enables longitudinal monitoring of disease progression and therapeutic response.
- Reduces biological risk by providing predictive, noninvasive readouts in preclinical models.
- Supports risk-adjusted advancement decisions based on quantitative, multimodal data.
Pipeline & Workflow Integration
This imaging protocol bridges early discovery, lead identification, and preclinical validation by providing a unified platform for hypothesis testing and efficacy assessment in cardiovascular research.
- Discovery Biology: Quantifies cardiac injury and recovery, supporting mechanistic hypothesis testing and pathway clarification.
- Screening: Delivers reproducible, quantitative imaging endpoints for compound screening and ranking.
- Analytics: Provides standardized measurements (e.g., LV mass, infarct size, FDG uptake) for robust statistical comparison across conditions.
- Translational Research: Aligns preclinical imaging outputs with clinical diagnostic modalities, enhancing translational relevance.
- Enterprise Reuse: Offers a scalable, reusable imaging workflow adaptable to diverse cardiac research programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in cardiovascular target validation.
- Operational Value: Standardizes imaging protocols for reproducibility and throughput in preclinical studies.
- Strategic Value: Informs go/no-go decisions and optimizes resource allocation by providing early, quantitative efficacy data.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement of cardioprotective candidates.
Implementation Considerations
- Requires expertise in small animal imaging, cardiac physiology, and multimodal data analysis.
- Demands access to high-field MRI and PET instrumentation with compatible animal handling systems.
- Necessitates rigorous cross-team standardization of imaging protocols and data segmentation.
- Adaptation may be needed for different mouse strains or cardiac injury models.
- Throughput and reproducibility depend on precise gating, slice planning, and co-registration procedures.
Biopharma FAQs
Why is null hypothesis testing critical in MRI/PET cardiac studies?
Null hypothesis testing ensures that observed changes in infarct size or metabolic activity following treatment are statistically significant, supporting robust target validation and reducing false positives in early discovery.
How does independent variable isolation improve drug assessment in this imaging workflow?
Isolating variables such as treatment timing or dose allows clear attribution of changes in cardiac function or FDG uptake to the intervention, strengthening mechanistic insights and pipeline decision-making.
What do quantitative dependent variable measurements enable in MRI/PET protocols?
Quantitative outputs like ejection fraction, infarct size, and metabolic activity enable objective comparison across treatment groups, facilitating data-driven advancement and portfolio triage.
Why are replication requirements important for cross-functional imaging teams?
Replication ensures that imaging results are reproducible across studies and operators, supporting cross-functional collaboration and confidence in preclinical efficacy claims.
What statistical analysis capabilities are needed before implementing MRI/PET endpoints?
Teams must establish robust statistical workflows for analyzing imaging-derived metrics, including segmentation accuracy and inter-group comparisons, to ensure reliable interpretation and decision support.
![PET Imaging of Neuroinflammation Using [11C]DPA-713 in a Mouse Model of Ischemic Stroke](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F57243.jpg%3Fv%3D2026-08-11T08%253A27%253A19.686Z&w=384&q=75)
